Molecular characterization of epithelial ovarian borderline tumors with respect to clinical management and prognosis

Česká verzia

Authors: Michal Zikán ; I. Pinkavová; J. Sláma; P. Freitag; M. Janoušek; D. Fischerová; D. Pavlišta ; D. Cibula
Authors place of work: Onkogynekologické centrum, Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha, přednosta prof. MUDr. A. Martan, DrSc. ¹
Published in the journal: Ceska Gynekol 2009; 74(6): 427-430

Summary

Objective:
To analyze up-to-data knowledge in the field of molecular characterization of epithelial ovarian borderline tumors with respect to clinical management and prognosis.

Design:
Review.

Setting:
Oncogynecological Center, Department of Obstetrics and Gynecology, Charles University in Prague, First Faculty of Medicine, and General Faculty Hospital, Prague.

Methods:
Based on literature search and own experimental data in the field of molecular biology of ovarian cancer and borderline tumors of ovary, we summarize up-to-date knowledge of molecular differences and specific features of BTO with respect to implementation of these knowledge into the clinical management.

Results and conclusion:
We suppose that spectrum of genomic changes (i.e. genetic and epigenetic) causing tumor transformation is limited and these changes take place in stem or progenitor cell. Analysis of genomic changes can help to define certain subtypes of BTO and, correlated to clinical characteristics, to identify subtypes with different biological behavior. Such molecular typing of BTO allows to individualyze treatment.

Key words:
borderline tumor of ovary, cancer stem cell, peritoneal implantates.

Zdroje

1. Bell, DA. Origins and molecular pathology of ovarian cancer. Mod Pathol 2005, 18, Suppl 2, p. S19-S32.

2. Eads, CA., Danenberg, KD., Kawakami, K., et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucl Acids Res 2000, 28, 8, p. e32.

3. Fiegl, H., Windbichler, G., Mueller-Holzner, E., et al. HOXA11 DNA methylation - a novel prognostic biomarker in ovarian cancer. Int J Cancer 2008, 123, 3, p. 725-729.

4. Motamed-Khorasani, A., Jurisica, I., Letarte, M., et al. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Oncogene 2006, 26, 2, p. 198-214.

5. Shih, IEM., Kurman, RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005, 11, 20, p. 7273-7279.

6. Shih, IEM., Kurman, RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164, 5, p. 1511-1518.

7. Widschwendter, M., Fiegl, H., Egle, D., et al. Epigenetic stem cell signature in cancer. Nat Genet 2007, 39, 2, p. 157-158.

8. Widschwendter, M., Jiang, G., Woods, C., et al. DNA hypomethylation and ovarian cancer biology. Cancer Res 2004, 64, 13, p. 4472-4480.

9. Zikan, M., Janatova, M., Pavlista, D., Pohlreich, P. High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer. J Genet 2007, 86, 2, p. 169-171.

10. Zikan, M., Pohlreich, P., Stribrna, J. Mutational analysis of the BRCA1 gene in 30 Czech ovarian cancer patients. J Genet 2005, 84, 1, p. 63-67.